CN112955184A - 可编程免疫细胞受体复合物系统 - Google Patents

可编程免疫细胞受体复合物系统 Download PDF

Info

Publication number
CN112955184A
CN112955184A CN201980032485.3A CN201980032485A CN112955184A CN 112955184 A CN112955184 A CN 112955184A CN 201980032485 A CN201980032485 A CN 201980032485A CN 112955184 A CN112955184 A CN 112955184A
Authority
CN
China
Prior art keywords
programmable
cells
cell
immune cell
receptor complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980032485.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·D·基特尔
J·S·勒万德
唐园园
梁胜文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundamental Solutions Corp
Original Assignee
Fundamental Solutions Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundamental Solutions Corp filed Critical Fundamental Solutions Corp
Publication of CN112955184A publication Critical patent/CN112955184A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dermatology (AREA)
CN201980032485.3A 2018-03-15 2019-03-14 可编程免疫细胞受体复合物系统 Pending CN112955184A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643378P 2018-03-15 2018-03-15
US62/643,378 2018-03-15
US201862651916P 2018-04-03 2018-04-03
US62/651,916 2018-04-03
PCT/US2019/022245 WO2019178342A1 (en) 2018-03-15 2019-03-14 Programmable immunocyte receptor complex system

Publications (1)

Publication Number Publication Date
CN112955184A true CN112955184A (zh) 2021-06-11

Family

ID=67905164

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980032485.3A Pending CN112955184A (zh) 2018-03-15 2019-03-14 可编程免疫细胞受体复合物系统

Country Status (6)

Country Link
US (3) US20190284255A1 (https=)
EP (1) EP3765093A4 (https=)
JP (1) JP7462578B2 (https=)
KR (2) KR20250151559A (https=)
CN (1) CN112955184A (https=)
WO (1) WO2019178342A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11117936B2 (en) * 2017-11-10 2021-09-14 University of Pittsburg—Of the Commonwealth System of Higher Education Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
CN112955184A (zh) 2018-03-15 2021-06-11 基本解决方案公司 可编程免疫细胞受体复合物系统
US20220242929A1 (en) * 2019-08-05 2022-08-04 Cartherics Pty. Ltd. Immune cells expressing modified cell receptors and methods of making

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017801A2 (en) * 1997-10-03 1999-04-15 Cancer Research Campaign Technology Limited Materials and methods relating to the stimulation of cells
WO2004018509A1 (en) * 2002-08-23 2004-03-04 Jyväskylän Yliopisto Improved mutants of biotin binding protein
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
CN104583230A (zh) * 2012-07-13 2015-04-29 宾夕法尼亚大学董事会 通过共同引入双特异性抗体增强car t细胞的活性
CN105980402A (zh) * 2013-12-20 2016-09-28 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
US20160289775A1 (en) * 2015-03-31 2016-10-06 Fundamental Solutions Corporation Biosensor system for the rapid detection of analytes
WO2016196384A1 (en) * 2015-05-29 2016-12-08 Fred Hutchinson Cancer Research Center Compositions for cellular immunotherapy
WO2017041143A1 (en) * 2015-09-11 2017-03-16 Ctm@Crc Ltd. Chimeric antigen receptors and uses thereof
CN107106670A (zh) * 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 用于修饰的t细胞的方法和组合物
CN107429286A (zh) * 2015-03-31 2017-12-01 基本解决方案公司 用于快速检测分析物的生物传感器系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874239A (en) 1993-07-30 1999-02-23 Affymax Technologies N.V. Biotinylation of proteins
WO2013044225A1 (en) * 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
CN112955184A (zh) 2018-03-15 2021-06-11 基本解决方案公司 可编程免疫细胞受体复合物系统

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017801A2 (en) * 1997-10-03 1999-04-15 Cancer Research Campaign Technology Limited Materials and methods relating to the stimulation of cells
WO2004018509A1 (en) * 2002-08-23 2004-03-04 Jyväskylän Yliopisto Improved mutants of biotin binding protein
CN104583230A (zh) * 2012-07-13 2015-04-29 宾夕法尼亚大学董事会 通过共同引入双特异性抗体增强car t细胞的活性
US20150322169A1 (en) * 2012-07-13 2015-11-12 The Trustees Of The University Of Pennsylvania Enhancing Activity of CAR T Cells by Co-Introducing a Bispecific Antibody
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
CN105980402A (zh) * 2013-12-20 2016-09-28 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
CN107106670A (zh) * 2014-10-31 2017-08-29 宾夕法尼亚大学董事会 用于修饰的t细胞的方法和组合物
US20170258835A1 (en) * 2014-10-31 2017-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
US20160289775A1 (en) * 2015-03-31 2016-10-06 Fundamental Solutions Corporation Biosensor system for the rapid detection of analytes
CN107429286A (zh) * 2015-03-31 2017-12-01 基本解决方案公司 用于快速检测分析物的生物传感器系统
WO2016196384A1 (en) * 2015-05-29 2016-12-08 Fred Hutchinson Cancer Research Center Compositions for cellular immunotherapy
WO2017041143A1 (en) * 2015-09-11 2017-03-16 Ctm@Crc Ltd. Chimeric antigen receptors and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JASON J. LOHMUELLER等: "mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting", ONCOIMMUNOLOGY, vol. 7, no. 1, 26 October 2017 (2017-10-26), pages 1 - 6 *

Also Published As

Publication number Publication date
KR102867256B1 (ko) 2025-10-01
US12234273B2 (en) 2025-02-25
EP3765093A1 (en) 2021-01-20
EP3765093A4 (en) 2021-12-08
US20200299352A1 (en) 2020-09-24
WO2019178342A1 (en) 2019-09-19
JP7462578B2 (ja) 2024-04-05
JP2021518428A (ja) 2021-08-02
KR20210018196A (ko) 2021-02-17
KR20250151559A (ko) 2025-10-21
US20190284255A1 (en) 2019-09-19
US20250197472A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
JP7556583B2 (ja) Ｋｒａｓ突然変異を識別するｔ細胞受容体およびそのコード配列
JP7822340B2 (ja) キメラ抗原受容体およびその使用
CN118634339B (zh) 用于细胞疗法的基于靶向性配体-有效负载的药物递送
US20260085106A1 (en) Signalling System
US20250197472A1 (en) Programmable immunocyte receptor complex system
CN113518785A (zh) 携带pd-1胞外域的嵌合细胞因子受体
CN113166226A (zh) 表达显性负性fas的免疫应答细胞及其用途
CN112469829A (zh) 包含抗gpc3单链抗体的car
CN110343166B (zh) 识别afp抗原短肽的t细胞受体
US20230346938A1 (en) Chimeric antigen receptors targeting cd19 and use thereof
JP2023510870A (ja) Ｉｃｄ ｓｔａｔシグナル伝達が改変されたｃｄ１２２
JP2023554674A (ja) 遺伝子改変細胞追跡用ペプチドマーカー
WO2024110751A1 (en) Constitutively active chimeric antigen receptor for treg cell survival and/or persistence
WO2021022447A1 (zh) 识别afp抗原短肽的t细胞受体
US20240218030A1 (en) Mutated ferritin protein
CN102120772B (zh) 一种嵌合抗体及免疫细胞
JP2022549994A (ja) Ｓｓｘ２抗原の短いペプチドを識別するｔ細胞受容体
US20240216517A1 (en) Pharmaceutical composition for prevention or treatment of lung cancer
WO2024081824A2 (en) Synthetic intermediates for universal chimeric antigen receptor immune cell therapies
CN120302987A (zh) 嵌合抗原受体系统、制备方法及其用途
CN119529098B (zh) 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白
EP4335450A1 (en) Pharmaceutical composition for prevention or treatment of lung cancer
WO2022206861A1 (zh) 识别afp的t细胞受体
WO2024119819A1 (zh) 一种多肽标签及其应用
EP4370543A1 (en) T cell receptors (tcr) to human papillomavirus proteins, compositions, and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination